Company
CEO Message
NanoCarrier was established to develop drugs which utilize the nanotechnology researched by Dr. Kataoka Kazunori, Professor Emeritus at the University of Tokyo, Teruo Okano, Emeritus Professor at Tokyo Women's Medical University, and their colleagues. The company uses polymeric micelles (micellar nanoparticles technology), which is technology originating in Japan, as drug carriers, and creates new value in cancer therapy through the integration of medicine and engineering.
NanoCarrier is currently focusing on the development of drug delivery systems (DDS) for drugs such as anti-cancer therapeutics and nucleic acids which need to be delivered reliably in large doses directly to the site of disease. The platform technology for maximizing a drug's efficacy whilst minimizing side effects can be applied not only to next-generation therapeutics but also to a wide range of other applications. NanoCarrier aims to reduce the burden on patients undergoing treatment, enabling them to be treated whilst leading a normal life, without being hospitalized.
The company already has a number of products in the pipeline which are in the late development stage and is proud of being one of only a handful of Japanese bioventures which have come this far. NanoCarrier is committed to creating new value and helping people lead healthier, happier lives.
Tetsuhito Matsuyama,
President & CEO
Corporate Profile
| Corporate Name | NanoCarrier Co.,Ltd. |
|---|---|
| Location |
Tokyo Office (Head office)
Ohnoya-Kyobashi Bldg 1-4-10 Kyobashi,Chuo-ku, Tokyo, 104-0031, Japan Lab (iCONM laboratory)Innovation Center of NanoMedicine(iCONM) 3-25-14 Tonomachi, |
| Establishment | June 14, 1996 |
| President and CEO | Tetsuhito Matsuyama |
| Capital | 4,135 million yen (As of March 31, 2020) |
| Number of employees & management | 37 (As of March 31, 2020) |
| Scopes of Business | R&D and production of pharmaceuticals using micellar nanoparticles technology. |
Management
Tetsuhito Matsuyama
President and CEO
Career Summary
| Apr. 1986 | Joined Mitsubishi Corporation |
|---|---|
| Sep. 2002 | President of Nanotech Partners Inc. |
| May 2003 | Served as Director, COO and CFO, and President & CEO of Medical ProteoScope Co., Ltd. |
| Oct. 2007 | Executive Officer of CSK Institute for Sustainability, Ltd. |
| May 2010 | Served as, among others, General Manager of Business Development Division, Executive Officer and COO of Overseas Business Group of Lawson Inc. |
| Nov. 2012 | Served as, among others, consultant and Director of Nitto Boseki Co., Ltd. and Senior Managing Director of Nittobo Medical Co., Ltd. |
| Dec. 2014 | Advisor to the Company |
| Jun. 2015 | Director, CFO and Head of CEO Office of the Company |
| Jun. 2018 | Director of Entrust Inc. (current) |
| Nov. 2019 | President & CEO of the Company (current) |
Shiro Akinaga, Ph.D.
Board of Director CSO
Career Summary
| Apr. 1981 | Joined Kyowa Hakko Kogyo Co., Ltd. (currently Kyowa Kirin Co., Ltd.) |
|---|---|
| Apr. 1994 | Senior Researcher at pharmaceutical research center of Kyowa Hakko |
| Apr. 2001 | Therapeutic Area Manager of oncology group at Drug Discovery Research Division of Kyowa Hakko |
| Apr. 2004 | Deputy Director, Clinical Development I Department, R&D Division of Kyowa Hakko |
| Apr. 2006 | Served as Director of International Development Department and Director of Clinical Development I Department, R&D Division of Kyowa Hakko |
| Oct. 2008 | Director, Clinical Development I Department, Development Division of Kyowa Hakko Kirin Co., Ltd. (currently Kyowa Kirin Co., Ltd.) |
| Mar. 2011 | Executive Officer (International Development) of Kyowa Hakko Kirin |
| Mar. 2013 | Fellow of Kyowa Hakko Kirin |
| Mar. 2017 | Director and CSO of AccuRna, Inc. |
| Nov. 2018 | Chairman of the board, CEO of AccuRna, Inc. |
| Jun. 2020 | Director of the Company |
| Sep. 2020 | Managing Director of R&D Division & CSO of the Company (current) |
Koji Fujimoto
Managing Director of Corporate Division
Career Summary
| Apr. 1996 | Joined Nissan Construction Co., Ltd. (currently Rinkai Nissan Construction Co., Ltd.) |
|---|---|
| Nov. 2002 | Joined the Company |
| Jul. 2005 | Manager of General Affairs and HR Section, Administration Department of the Company |
| May 2015 | Deputy Director of Administration Department of the Company |
| Apr. 2017 | Director of General Affairs and HR Department of the Company |
| Dec. 2019 | Managing Director of Corporate Division (current) |
| Jun. 2020 | Managing Director of Corporate Department of the Company (current) |
Teruo Okano, Ph.D.
Board of Director
Career Summary
| Jan. 1994 | Professor at Institute of Biomedical Engineering, Tokyo Women’s Medical University Affiliate Professor at Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah (U.S.) (current) |
|---|---|
| Jun. 1996 | Director of the Company (current) |
| Apr. 2001 | Director and Professor at Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University |
| May 2001 | Director of CellSeed Inc. |
| Apr. 2014 | Professor Emeritus and Professor by Special Appointment at Tokyo Women’s Medical University (current) |
| Sep. 2016 | Director of Cell Sheet Tissue Engineering Center, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah (U.S.) (current) |
| Apr. 2020 | Director of Institute of Advanced BioMedical Engineering and Science, Tokyo Women’s Medical University (current) |
Kazunori Kataoka, Ph.D.
Board of Director
Career Summary
| Apr. 1979 | Served as assistant, lecturer and Assistant Professor at Institute of Biomedical Engineering, Tokyo Women’s Medical University |
|---|---|
| Apr. 1989 | Served as Assistant Professor and Professor at Faculty of Industrial Science and Technology, Tokyo University of Science |
| Apr. 1998 | Professor at School of Engineering, the University of Tokyo |
| Jul. 2004 | Professor at Graduate School of Medicine, the University of Tokyo (concurrent) |
| Jul. 2015 | Director General of Innovation Center of NanoMedicine (current) |
| Apr. 2016 | Professor by Special Appointment at the University of Tokyo (current) |
| Jun. 2016 | Professor Emeritus of the University of Tokyo (current) |
| Jul. 2016 | Vice-Director General at Kawasaki Institute of Industry Promotion (current) |
| Jun. 2020 | Director of Nissan Chemical Corporation (current) Director of the Company (current) |
Atsushi Matsumura
Board of Director
Career Summary
| Apr. 1986 | Joined Nomura Securities, Co., Ltd |
|---|---|
| Jan. 2008 | Representative Director of Quiet Partners Inc. |
| Sep. 2010 | President of Whiz Partners Inc. (current) |
| Mar 2012 | Director of the Company (current) |
| Mar. 2017 | Director of ALBERT Inc. |
| Dec. 2019 | Chairman of the board of AXEL MARK INC. |
| May 2020 | Chairman of the board of ALBERT Inc. (current) |
| Mar. 2021 | Director of AXEL MARK INC. (current) |
Satoru Iino
Board of Director
Career Summary
| Apr. 1989 | Joined Hitachi, Ltd. |
|---|---|
| Mar. 2020 | Joined CSK Venture Capital Co., Ltd. |
| Feb. 2004 | Director of CSK Venture Capital |
| Sep. 2010 | Executive Officer of Whiz Partners Inc. |
| Mar. 2012 | Director of the Company |
| Apr. 2013 | Managing Director of Investment Management Department of Whiz Partners Inc. |
| Jun. 2013 | Director of Advanced Media, Inc. (current) |
| Mar. 2015 | Managing Director and CIO of Fund Business of Whiz Partners Inc. (current) |
| Mar. 2017 | Director of ALBERT Inc. (current) |
| Dec. 2019 | Director of AXEL MARK INC. (current) Director of CRI Middleware Co., Ltd. (current) |
Yuki Hasegawa
Board of Director
Career Summary
| Jan. 2007 | Researcher at RIKEN Genome Sciences Research Complex |
|---|---|
| Apr. 2008 | Postdoctoral Fellow at RIKEN Omics Science Center |
| Apr. 2010 | Research Scientist at RIKEN Omics Science Center |
| Apr. 2013 | Deputy Team Leader at RIKEN Center for Life Science Technologies |
| Sep. 2014 | Researcher at Asahi Kasei Corp. |
| Jul. 2016 | Associate Director of Whiz Partners Inc. |
| Apr. 2019 | Director of Whiz Partners Inc. |
| May 2021 | Head of Healthcare Investment at Whiz Partners Inc. (current) |
Masaharu Miyajima
Auditors
Career Summary
| Apr. 1979 | Joined Zeria Pharmaceutical Co., Ltd. |
|---|---|
| Nov. 1985 | Served as, among others, Chief Researcher and Managing Director of Research Department, Central Research Laboratories of Zeria Pharmaceutical |
| Mar. 2000 | Chief researcher at R&D Center of Terumo Corporation |
| Apr. 2006 | Associate professor at School of Pharmaceutical Sciences of Ohu University |
| Aug. 2008 | Served as, among others, Director of Manufacturing Technology Department and Director responsible for EHS at Bushu Pharmaceuticals Ltd. |
| Jun. 2016 | Secretary General of Japan Society of Pharmaceutical Machinery and Engineering |
| Jun. 2017 | Director of Research Department of the Company |
| Apr. 2020 | Director responsible for the Research Department of the Company (current) |
Mieko Nakayama
Auditors
Career Summary
| Apr. 1985 | Joined American Family Life Assurance Company of Columbus |
|---|---|
| Apr. 2002 | Joined the Legal Research and Training Institute of Japan |
| Oct. 2003 | Registered with the Bar (admitted to Dai-ichi Tokyo Bar Association) Joined Makoto Law & Accounting Firm |
| Apr. 2010 | Partner at Haruka Sogo Law Firm (current) |
| Jun. 2017 | Audit & supervisory board member of the Company (current) |
Takashi Kawai
Auditors
Career Summary
| Apr. 1988 | Joined People’s Finance Corporation (currently Japan Finance Corporation) |
|---|---|
| Sep. 1992 | Joined Arthur Andersen (currently KPMG Asza LLC) |
| Sep. 1996 | Joined Coca-Cola(Japan)Company, Limited |
| Jan. 2002 | Director of C&SF Division of GE Consumer Finance |
| Mar. 2006 | Senior Managing Director of Administrative Department of MediBIC Group |
| Jun. 2008 | Finance Director at Reed Business Information Japan K.K. |
| Sep. 2009 | Managing Director of Finance and Accounting Department of Entrust Inc. |
| Apr. 2011 | President of Kawai Certified Public Accountant Office (current) |
| Feb. 2016 | President and CEO of Hands-on CFO Partners Inc. (current) |
